aTYR Pharma (ATYR) director receives 50,000-share stock option grant

Rhea-AI Filing Summary

aTYR Pharma director Sara Zaknoen received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $0.95 per share and were awarded with no purchase price at grant. They vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving on the board. After this award, she holds options for 50,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Zaknoen Sara

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 50,000 shares Exercise price: $0.95 per share Shares underlying options: 50,000 shares +2 more

5 metrics

Option grant size 50,000 shares Stock Option (right to buy) granted on May 11, 2026

Exercise price $0.95 per share Conversion or exercise price for the stock options

Shares underlying options 50,000 shares Underlying aTYR Pharma common stock

Options after transaction 50,000 shares Total options held following the grant

Option expiration May 11, 2036 Expiration date of the stock options

Key Terms

Stock Option (right to buy), non-employee director compensation policy, vests in full, Annual Meeting of Stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

non-employee director compensation policy financial

"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full"

vests in full financial

"The option ... vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting"

Annual Meeting of Stockholders financial

"the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zaknoen Sara

(Last) (First) (Middle)

C/O ATYR PHARMA, INC.

10240 SORRENTO VALLEY ROAD, SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ ATYR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.95	05/11/2026		A		50,000		(1)	05/11/2036	Common Stock	50,000	$0.00	50,000	D

Explanation of Responses:

1. The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.

	/s/ Nancy E. Denyes, as Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did aTYR Pharma (ATYR) director Sara Zaknoen report on this Form 4?

Sara Zaknoen reported receiving a stock option grant for 50,000 shares of aTYR Pharma common stock. The options were granted as director compensation and increase her directly held option position to 50,000 shares after the transaction.

What are the key terms of Sara Zaknoen’s aTYR Pharma (ATYR) stock option grant?

The grant covers options on 50,000 shares of common stock with an exercise price of $0.95 per share. The options were awarded at no cost on grant date and are held directly by her as director compensation.

When do Sara Zaknoen’s aTYR Pharma (ATYR) stock options vest?

The options vest in full on the earlier of May 11, 2027 or aTYR Pharma’s 2027 Annual Meeting of Stockholders. Vesting is conditioned on Sara Zaknoen’s continued service on the company’s Board of Directors.

How many aTYR Pharma (ATYR) options does Sara Zaknoen hold after this grant?

Following the reported transaction, Sara Zaknoen holds options covering 50,000 shares of aTYR Pharma common stock. This reflects the full amount of the newly granted options reported in this Form 4 filing.

Is Sara Zaknoen’s aTYR Pharma (ATYR) option grant part of a compensation policy?

Yes, the filing states the option was granted under aTYR Pharma’s non-employee director compensation policy. This indicates the award is routine board compensation tied to her ongoing service as a director.